Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at ir.unither.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

United Therapeutics won a US District Court ruling that Liquidia infringed its patent on inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease, potentially forcing the FDA to withdraw approval of Liquidia's Yutrepia for that use.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 30 Sep 2026 and 14 Oct 2026.

◆ ◆ The Wire takeaway

Patent rulings have created a high-risk regulatory roadblock for inhaled treprostinil competitors. You must reassess market entry and regulatory pathways urgently if your drug targets PH-ILD treatment.

◆ Coverage

3 sources · first reported 30 Sep 2026 · latest 14 Oct 2026

◆ Related on Wire

◆ Topics

Biotechpatentlitigationpulmonary-hypertensionregulatory-withdrawalFDAbiotech